New Therapeutic Advances in the Management of Tricuspid Valve Regurgitation.
Andreas SynetosNikolaos KtenopoulosOdysseas KatsarosKonstantina VlasopoulouTheofanis KorovesisMaria DrakopoulouKonstantinos ToutouzasLeonidas KoliastasisKonstantinos ToutouzasConstantinos TsioufisPublished in: Journal of clinical medicine (2024)
Tricuspid regurgitation (TR) is an intricate disorder that has a negative outlook, while surgical treatment is linked to increased mortality. Primary TR occurs due to a structural defect in the tricuspid valve (TV), while secondary TR is a more prevalent condition often associated with pulmonary hypertension, heart failure, and atrial fibrillation. The use of specific surgical procedures to improve TR is limited in everyday clinical practice due to the heightened surgical risk and delayed patient presentation. The development of other transcatheter heart valve procedures has led to a significant increase in transcatheter TV operations, which can be attributed to certain technological advancements. This review aims to provide an updated overview of transcatheter TV procedures, available alternative therapies, and standards for patient selection. It will also highlight the current state of development in this field, which is characterized by rapid progress and numerous ongoing clinical trials.
Keyphrases
- aortic valve
- aortic stenosis
- heart failure
- transcatheter aortic valve replacement
- mitral valve
- atrial fibrillation
- case report
- pulmonary hypertension
- clinical trial
- left ventricular
- ejection fraction
- clinical practice
- left atrial
- coronary artery disease
- cardiovascular events
- pulmonary artery
- risk factors
- cardiovascular disease
- oral anticoagulants
- catheter ablation
- left atrial appendage
- coronary artery
- type diabetes
- pulmonary arterial hypertension
- acute coronary syndrome
- phase ii
- acute heart failure
- open label